

Parkinson's Disease: Pathophysiology, Symptoms, Comprehensive Treatment Plan and Dual Approach of Bromocriptine in Parkinson's Disease and Diabetes Mellitus.

Dr Obaid Ahmed Lone*, Dr Bilqees Jan*, Dr. AB Haseeb Dar, Dr Aqib Gulzar

CT Institute of Pharmaceutical Sciences, Punjab

***Corresponding Author**

Email Id: loneobaid3@gmail.com

DOI NUMBER: [10.5281/zenodo.21300090](https://doi.org/10.5281/zenodo.21300090)

Abstract

In addition to a wide range of non-motor symptoms that impair a patient's quality of life, Parkinson's disease (PD) is a chronic and progressive neurodegenerative illness that is primarily defined by motor symptoms such as bradykinesia, stiffness, and tremor. Parkinson's disease (PD) upsets the balance of neurotransmitters necessary for coordinated motor activity and is caused by the progressive loss of dopaminergic neurons in the substantia nigra. This study explores the intricate pathophysiology of Parkinson's disease (PD), looking at the functions of Lewy bodies, genetic variables like SNCA and LRRK2 mutations, and environmental factors including mitochondrial malfunction and oxidative stress. In addition to these insights, we list the main motor and non-motor symptoms that affect therapy methods and provide diagnostic issues, ranging from autonomic disturbances to postural instability and cognitive deterioration. Since there is presently no known cure or method to stop the progression of the disease, treatment for Parkinson's disease (PD) focuses on managing symptoms with pharmacologic and non-pharmacologic therapies. Dopamine agonists, MAO-B inhibitors, and dopamine replacement therapy especially Levodopa are the principal treatments. Drug effectiveness, however, may wane with time, and long-term care is frequently complicated by motor fluctuations and dyskinesias. The dual therapeutic role of bromocriptine, a dopamine agonist that has historically been used to treat motor symptoms in Parkinson's disease (PD), is particularly noteworthy. It also shows promise for glycemic management in those with concomitant type 2 diabetes mellitus (T2DM). By altering central neuroendocrine rhythms, bromocriptine's special mechanism improves insulin sensitivity, lowers plasma glucose levels, and may even lessen cardiovascular

risk in diabetic individuals. Both neurological and metabolic issues may be addressed by this dual-method treatment, offering a customized way to handling challenging situations. With a focus on the growing use of bromocriptine for diabetic patients, this study attempts to present a thorough analysis of the pathogenesis, symptomatology, and available treatments for Parkinson's disease. We stress the need for a customized treatment plan and the significance of routinely checking for adverse effects, especially in patients using dopamine agonists and other adjunct medicines. We demonstrate the potential to improve life quality for people juggling the combined difficulties of diabetes mellitus and Parkinson's disease by incorporating bromocriptine into the treatment paradigm.

Keywords: Parkinson's disease (PD), Neurodegenerative disorders, Substantia nigra, Dopaminergic neurons.

1. Introduction

Parkinson's disease ranks among the most common neurodegenerative conditions, impacting millions around the globe. Dr. James Parkinson initially described Parkinson's disease (PD), also known as paralysis agitans, in 1817 as the "shaking palsy" that plagued his gardener, who lived a "sobriety-focused" existence (Critchley, 1955). Since then, a great deal of research has been done on the connection between personality and the likelihood of getting PD. There is ample evidence to support the inverse relationship between the onset of PD and the "novelty-seeking" personality (as opposed to the law-abiding, controversial, and cautious "reduced-novelty seeking" personality exhibiting a "certain intellectual and moral rigidity"; (Benedetti et al., 2000). It has been demonstrated that a number of behaviors, including smoking, drinking, coffee, cocaine, amphetamines, and abusing opiates, can somewhat delay the onset of Parkinson's disease in the general population (Paulson and Dadmehr, 1991; Menza et al., 1993; Fujii et al., 2000). Contrary to this phenomenon, it has now been shown that patients who take the medications currently prescribed to treat this condition also seek out a "reward-seeking" lifestyle after starting therapy (Uitti et al., 1989; Dodd et al., 2005;) (Klos et al., 2005; Stocchi, 2005). Such etiological evidence just supports the pathological condition linked to Parkinson's disease (PD) through the death of the brain's "rewarding" dopaminergic neurons. It mainly showcases motor symptoms like bradykinesia, tremor, and rigidity, yet non-motor symptoms are also notably important, adding to the overall burden of the disease. Grasping the fundamental mechanisms, symptoms, and effective treatment alternatives is crucial for enhancing the quality of life for those affected and addressing symptoms. It deteriorates daily. Both males and females are impacted, but predominantly males

and older individuals. Its cause remains unknown, yet individuals with a family history are at a higher risk.

2. Pathophysiology

Parkinson's disease (PD) is primarily defined by the gradual loss of dopaminergic neurons in the substantia nigra pars compacta, an area in the midbrain essential for motor control. This degeneration of neurons leads to a reduction in dopamine levels in the striatum, a brain region critical for movement and coordination regulation. The lack of dopamine disrupts the balance between the direct and indirect pathways of the basal ganglia, resulting in typical motor symptoms such as bradykinesia, rigidity, and tremors (Kalia & Lang, 2015). The identification of Lewy bodies—abnormal clumps of the protein alpha-synuclein found in neurons—acts as a pathological signature of PD. These protein aggregates are believed to play a role in neuronal cell death, although the exact mechanisms are still being explored. Genetic factors, including mutations in the SNCA and LRRK2 genes, alongside environmental influences, are linked to a heightened risk for PD (Schapira & Olanow, 2004). Additionally, oxidative stress, mitochondrial dysfunction, and neuroinflammation are thought to be involved in the development of PD, indicating that the disease may arise from a complex interaction between genetic vulnerability and environmental factors (Olanow & Schapira, 2013).

3. Symptoms

The motor symptoms of Parkinson's disease:

It is estimated that as many as 80% of dopaminergic cells in the nigro-striatal system are lost prior to the emergence of the key motor symptoms associated with Parkinson's disease (PD) (Chung et al. 2001). Typically, the disease is diagnosed upon the onset of the first motor symptoms. The diagnosis relies on specific criteria established by the UK PD Brain Bank (Hughes et al. 1992). Bradykinesia, characterized by a slowing down of initiation of voluntary movements along with a gradual decrease in both the speed and amplitude of repetitive actions, must be present alongside one additional symptom either muscular rigidity, resting tremor, or postural instability in order to confirm the diagnosis (Hughes et al. 1992). The second step in diagnosis involves ruling out symptoms that could suggest alternative causes, such as other parkinsonian syndromes that have distinct neuropathological characteristics, while the third step requires confirmation of at least three supportive criteria for PD, which might include unilateral onset of symptoms, consistent asymmetry in clinical symptoms, a favourable response to levodopa treatment, and the onset of dyskinesias as a result of dopaminergic therapy. In most instances, symptoms begin on one side of the body, with contralateral symptoms developing within a few years. Patients often display a stooped posture, exhibit axial and limb rigidity with or without cogwheel rigidity, show a tendency

for a shuffling gait, and lack arm swing during walking. Bradykinesia may result in a facial appearance that lacks expression (hypomimia), and individuals may demonstrate smaller handwriting (micrographia). Approximately 80% of patients experience limb tremors, typically a resting pill-rolling tremor in the hands. The term "pill rolling" refers to the tendency of the thumb and index finger to touch and perform a circular motion (Jankovic 2008). Rarely, the tremor may also affect the legs, and other types of tremors can occur (Reichmann 2010). Additional gait disturbances beyond shuffling may include blocking, hesitancy, and festination, where steps become progressively smaller and quicker, potentially resulting in balance loss and falls. Between a quarter and 60% of patients encounter freezing of movements, which usually develops after several years from the onset of symptoms (Virmani et al. 2015). Postural stability may be compromised either early or later in the progression of the disease, which can lead to falls and injuries. Early falls are uncommon in those with an early age of onset, but age itself is a notable risk factor for falls in PD (Williams et al. 2006), and in older patients, the disease is sometimes initially identified in hospitals following a fall. A study conducted by Wood et al. (2002) indicated that 68% of 109 patients with PD, averaging 75 years in age and with a mean disease duration of three years, experienced falls. Another study found that falls occurred in 62% of patients with PD (Stolze et al. 2004). Factors that may predict falls, aside from older age, include disease duration, dementia, symmetrical onset, and postural as well as autonomic instability (Wood et al. 2002; Williams et al. 2006).

Oral motor issues are prevalent in this condition. More than half of the patients exhibit speech difficulties, such as speaking very softly and rapidly (Perez-Lloret et al. 2012), while swallowing difficulties have been reported by 40–80% of patients (Kalf et al. 2011), and around 25% experience drooling (Kalf et al. 2012). Dystonia represents another motor symptom found in Parkinson's disease (PD). It is characterized by sustained muscle contractions that are often accompanied by unusual movements, postures, or both. While it may occasionally serve as an early indicator of PD (Tolosa and Compta 2006), dystonic symptoms are predominantly associated with treatment, whether medical or surgical (Jankovic and Tintner 2001). Typical pre diagnostic dystonia can include a unilateral equinovarus foot position, flexion in the upper arm-to-forearm or forearm-to-hand, writer's cramp, oro-mandibular dystonia, torticollis, or various combinations of these symptoms (Tolosa and Compta 2006). In most instances, the symptoms of PD manifest within 10 years of the onset of dystonia. In cases of young-onset familial PD, dystonia mainly affects the foot, often causing cramp-like discomfort or inversion of the affected foot (Tolosa and Compta 2006).

In patients with medically managed PD, dystonia, along with dyskinesias, represents one of the primary motor complications linked to long-term treatment, typically arising during off periods but can also occur as peak dose dystonia or diphasic dystonia (Tolosa and Compta 2006). According to reports by Poewe and colleagues, the most common site for off dystonia is the foot, while neck and face are more frequently affected in cases of peak dose dystonia (Poewe and Lees 1987; Poewe et al. 1988). Postural deformities are a common complication associated with Parkinson's disease. These deformities may consist of an abnormally flexed posture characterized by flexion that begins in the thoracic or lumbar spine (camptocormia), forward flexion of the head and neck (Antecollis), and scoliosis, which is a lateral curvature of the spine often accompanied by rotational vertebral changes (Doherty et al. 2011). The underlying mechanisms of these deformities are likely multifactorial, potentially involving rigidity, axial dystonia, myopathy, and centrally impaired proprioception.

The non-motor symptoms of Parkinson's disease

Prior to the emergence of motor symptoms and the actual diagnosis, individuals may experience a range of pre-motor indicators. These symptoms can begin as early as a decade or more before a formal diagnosis is established (Schrag et al. 2015), and the presentation of non-motor symptoms can postpone the diagnosis (O'Sullivan et al. 2008). In a study involving 109 recently diagnosed patients who had yet to commence treatment, it was found that symptoms like apathy, excessive daytime sleepiness, sleep disturbances, and constipation could manifest in as many as 60–70% of patients before diagnosis, occurring more frequently than in healthy individuals. Additional pre-motor manifestations included anhedonia, cognitive issues, diminished sense of smell and taste, emotional disturbances, excessive sweating, fatigue, and discomfort. Symptoms such as constipation, REM sleep behaviour disorder, frequent nightmares, daytime drowsiness, and a sense of fullness after meals were commonly reported to occur over 10 years prior to the onset of motor symptoms (PontSunyer et al. 2015). Both depression and anxiety may also arise well in advance of a diagnosis being made (Chen et al. 2013). The pre-motor indicators differ among patients, yet they persist as other motor or non-motor symptoms of Parkinson's disease may develop over time. As the disease progresses, non-motor symptoms typically become more bothersome for patients compared to motor symptoms. These non-motor symptoms are classified into disturbances in autonomic function, sleep issues, cognitive and psychiatric disorders, and sensory symptoms.

Autonomic function disruptions:

According to Koike and Takahashi (1997), autonomic dysfunction may manifest before a diagnosis, show up as the illness worsens, or be brought on by medicine. Over 50% of patients have indicated that their everyday lives are impacted, and all aspects of autonomic function may

be impacted (Jost 2003). Because the central and peripheral postganglionic autonomic nerve systems are involved, autonomic dysfunction is taken into consideration (Jost 2003). Thirty to forty percent of patients experience orthostatic hypotension. According to Lahrmann et al. (2006), this is characterized by a drop in systolic blood pressure of more than 20 mm Hg or in diastolic blood pressure of more than 10 mm Hg after standing or tilting the head up to at least 60 degrees in three minutes. When standing up straight, hypotension-induced hypoperfusion of the brain can cause light headedness, blurred vision, and cognitive impairment, which may occur before unconsciousness. The blood pressure decline in Parkinson's disease (PD) can last for many minutes (Jost 2003). Orthostatic hypotension may occur independently of the length of Parkinson's disease (PD) (Jost and Augustis 2015). This may mostly happen after eating in older PD patients (Iodice et al. 2011). Symptoms related to the stomach are frequent. While postprandial fullness and gastric retention are signs of a slowdown of the gastrointestinal tract's motility, slow-transit constipation is by far the most prevalent, affecting 70–80% of people (Jost and Eckardt 2003; Jost 2010). Rectal sphincter dysfunction can also cause patients to have trouble with rectal evacuation (Mathers et al. 1989). Incontinence, urgency, and frequency of urination are examples of abnormalities in urine control (Jost 2003). 60% of patients report having frequent nocturia, which is brought on by detrusor hyperactivity (Yeo et al. 2012). Males frequently experience erectile dysfunction (Sakakibara et al. 2011). Additionally, autonomic dermatological symptoms such hyperhidrosis, or excessive perspiration, may be present. This does not seem to be related to the length of the illness, but it might be linked to dyskinesias or low blood levels of dopaminergic medications (Hirayama 2006). Despite frequent issues with saliva dribbling in advanced disease, salivary production seems to be decreased in Parkinson's disease (PD) (Cersosimo et al. 2009). 18.6% of patients have been observed to have seborrheic keratosis, a dermatological condition affecting the face and scalp (Fischer et al. 2001). Increased fat in the middle of the face is frequently linked to forehead skin scaling. The reason behind this is Unclear.

Disturbances in sleep:

Anatomical features and central neurotransmitters implicated in the regulation of the physiological sleep cycle are known to be impacted by the neuropathology of Parkinson's disease. Although polysomnographic results have revealed alterations in the structure of sleep waves when compared to healthy controls, medication treatment for various Parkinson's disease symptoms may also cause sleep disturbances at night (Larsen and Tandberg 2001; Monderer and Thorpy 2009). About two thirds of individuals may experience a variety of sleep disturbances (Mehta et al. 2008). The most prevalent type of sleep is fractionated (Porter et al. 2008). According to sleep studies, patients tend to wake up during the night more frequently and sleep more shallowly (Yong et al. 2011).

Fractionated sleep may also result from other symptoms of Parkinson's disease, including sadness, nocturnal tremor, frequent nocturia, and trouble turning around in bed (Lees et al. 1988). According to Montgomery and Thorpy (2009), up to 50% of people have excessive daytime sleepiness, which may be partially brought on by dopaminergic medications (Knie et al. 2011). Additionally, PD patients experience sleep disorders more frequently than controls. REM behaviour sleep disorder is one of them, in which patients thrash and kick around in the middle of the night while dreaming and act out their dreams. According to (Montgomery and Thorpy 2009), the prevalence of clinically exhibited Parkinson's disease (PD) is 27–32%; however, symptoms may start years or decades before motor symptoms do (Hickey et al. 2007). Patients are more likely than controls to experience restless legs syndrome, with or without periodic leg movements during sleep (Monderer and Thorpy 2008). Periodic leg movements of sleep are characterized by repetitive jerking of the lower limbs during sleep, typically seen by the partner. Restless legs syndrome is an urge to move the legs while sitting or lying down that is eased by walking around. While PD is known to cause obstructive sleep apnea, which is characterized by intermittent cessation of breathing during sleep (Monderer and Thorpy 2008), not every research has found that patients have a higher prevalence of this condition (Zeng et al. 2013). Patients receiving dopaminergic therapy have been known to experience sudden sleep episodes that happen without typical tiredness as a sleep inducer. According to Larsen and Tandberg (2001), almost all dopaminergic medications on the market have the potential to cause sleep attacks, and Brodsky et al. (2003) suggest that the dopaminergic treatment load may be a contributing factor.

Dementia and neuropsychiatric symptoms:

According to reports, between one-third and forty percent of people with Parkinson's disease experience visual hallucinations and illusions (Onofrij et al. 2007). Visual hallucinations have also been documented to occur before drug treatment, despite the fact that almost all antiparkinsonian medicines have been shown to cause hallucinations and psychosis (Pagonabarraga et al. 2016). The aetiology appears to be linked to neuropathological alterations in the hippocampus and amygdala brought on by the illness process (WilliamsGray et al. 2006). Images of humans, little creatures, or items are frequently conjured up, or the hallucinations may contain more than one item. You may or may not recognize the pictures. They can reoccur throughout the day and last anywhere from seconds to minutes (Holroyd et al. 2001). The hallucinations are typically not dangerous, and non-demented patients typically maintain insight. The hallucinations are less frequently tactile (Fenelon et al. 2002), auditory (Inzelberg et al. 1998), and olfactory (McAuley and Gregory 2012). According to one study, 10% of cases had a missing visual component (Papapetropoulos and Heather Katzen 2008). About 5% of patients experience delusions, whereas

17–72% experience minor visual phenomena like sense of presence and visual illusions (Fenelon and Alves 2010). Hallucinations may be linked to a higher dopaminergic treatment load, but other factors that may be significant include the severity of the disease, cognitive decline, depression, advanced age, and reduced visual acuity (Holroyd et al. 2001; Fenelon and Alves 2010). Patients may experience paranoid delusions as their illness worsens, frequently accompanied by thoughts of persecutory behaviour or suspicions directed against their spouse (Williams-Gray et al. 2006). Psychosis typically manifests late in the course of the illness in patients taking large dosages of medicines, or it may be linked to advanced age, cognitive decline, or a history of depression (Thanvi et al. 2005). Additionally, behavioural disorders like euphoria or hypomania, poor organizational abilities, hypersexuality, aberrant hoarding or punting, and risk-taking behaviour may be brought on by the dopaminergic therapy (O'Sullivan et al. 2009). Gambling, fast driving, and extravagant spending are examples of risk-taking behaviour. These symptoms, which collectively have been referred to as impulse control problems or dopamine dysregulation syndrome, are becoming more well acknowledged (Evans and Lees 2004). According to O'Sullivan et al. (2009) and Ceravolo et al. (2010), they seem to be connected to the dopaminergic treatment load and may be more related to dopamine receptor agonist medications than others. Men with very young onset of sickness are most likely to have dopamine dysregulation syndrome (Ceravolo et al. 2010). Dementia and cognitive decline are prevalent in Parkinson's disease (PD) and can happen early or late (Williams-Gray et al. 2006, 2007). In addition to visuospatial dysfunction, reduced speech fluency, and memory impairment, the initial symptoms include executive function issues, such as difficulty planning and organizing goal-directed behaviour (Williams-Gray et al. 2006). According to Irwin et al. (2012), the expansion of neuropathological alterations to cortical brain areas is correlated with the progression of dementia. According to reports, mild cognitive impairment is twice as common in PD patients as in non-PD patients (Aarsland et al. 2009). According to Aarsland et al. (2007), incidence dementia in PD has been linked to age rather than the age at commencement of the disease.

Sensory symptoms:

In PD, sensory complaints are common. At least 80% of patients have a diminished or absent sense of smell, which frequently manifests well before motor symptoms (Doty et al. 1988). It is possible to experience vague, aberrant sensations in some body areas, and these sensations may change depending on the course of treatment (Bayulkemand and Lopez 2011). According to (Broen et al. 2012), 40–85% of patients report experiencing pain. According to (Williams and Lees 2009), limb pain may be the initial symptom and be misinterpreted as degenerative spine illness or frozen shoulder. Although vaginal, abdominal, thoracic, and limb discomfort are the most common, they

can also occur (Waseem and Gwinn-Hardy 2001). Musculoskeletal, central neuropathic, dystonic, radicular-neuropathic, and pain-associated restlessness (akathisia) are the five categories of pain that have been identified (Ford 2010). Nearly half of patients report having musculoskeletal pain, although this type of pain is typical for this age range and may not always be connected to Parkinson's disease. Less frequently experienced types of neuropathic pain include dystonic, radicular, and central (Broen et al. 2012).

4. Comprehensive Treatment Plan

There is no cure for PD, since currently available therapies can neither arrest nor reverse the progression of the disease. However, the symptoms can be managed with several different drugs. The treatment of Parkinson's disease involves a multi-faceted approach aimed at alleviating symptoms and enhancing quality of life. The following drugs are used in management of early to advanced Parkinson's disease

Anticholinergic Medications

These drugs can improve tremor and sometimes dystonic (twisting repetitive movements that affect limbs, eyes, face and a combination of these muscle groups) features in some patients. They are not mostly effected in bradykinesia or other disabilities. (Schapira, A. H. V., & Olanow, C. W. (2004).

Examples:

GENRIC NAME	Starting dose mg/day	Maintenance (Dose mg)
Benzotropine	0.5-1	1-6
Trihexyphenidyl	1-2	6-15

Levodopa and Carbidopa products

They are dopamine precursors they are most effective drug in the treatment of Parkinson's disease. Levodopa and carbidopa are given in combination as carbidopa can't be given alone as it does not cross BBB (blood brain barrier). They are used as first line treatment for PD. **Examples:**

GENRIC NAME	Starting Dose (mg/day)	Maintenance Dose (mg)
Carbidopa/L-dopa	100-300	300-1000
Carbidopa/L-dopa / Entacapone	200-600	600-1600

Catechol-O-Methyltransferase Inhibitor

Tolcapone and entacapone are utilized alongside carbidopa/ L-dopa to inhibit the peripheral transformation of L -dopa into dopamine (which raises the area under the curve of L-dopa by about 35%). Consequently, the duration of being 'on' is extended by about 1 to 2 hours, while the required

dosage of L-dopa is reduced. Refrain from using nonselective MAO inhibitors simultaneously to avoid obstructing the pathways for regular catecholamine metabolism. (Pharmacotherapy Handbook, 09th Ed.pdf) **Examples:**

GENRIC NAME	Starting dose (mg/day)	Maintenance Dose (mg)
Entacapone	200-600	200-1600
Tolcapone	300	300-600

MAO-B Inhibitors

Examples:

- Unless significant levels of dietary tyramine are consumed, selegiline and rasagiline, which are selective, irreversible inhibitors of MAO-B, are unlikely to cause a "cheese reaction" (headache, hypertension) at therapeutic doses. But integrating MAO-B (Jankovic, J. (2008). Meperidine inhibitors and other opioid analgesics should not be used together due to the slight possibility of serotonin syndrome.
- Selegiline prevents the breakdown of dopamine and can prolong the duration of effect of up to one hour of L-dopa. It frequently allows the L-dopa dosage to be lowered by as much as half. (Jankovic, J. (2008).
- Selegiline can exacerbate underlying dyskinesias or mental symptoms like delusions, and it also heightens the peak effects of L-dopa. Selegiline's metabolites are the substances lamphetamine and l-methamphetamine. The oral dissolving pill could offer reduced adverse effects and better responsiveness compared to the traditional formulation.
- Rasagiline is somewhat helpful as monotherapy and also amplifies the benefits of Ldopa. Better long-term outcomes might be linked to early beginning. **Examples:**

GENRIC NAME	Starting (dose mg/day)	Maintenance dose (mg)
Selegiline	0.5-1	0.5-1
Rasagiline	5-10	5-10

Dopamine agonists

Patients who experience fluctuations in their response to L-dopa can benefit from the non ergots pramipexole, rotigotine, and ropinirole as well as the ergot derivative bromocriptine. The frequency of "off" periods is reduced, and they have an impact that spares L-dopa. To improve tolerance and determine the lowest dosage that yields the greatest benefit, gradually increase the dosage of dopamine agonists. (Jankovic, J. (2008).

- The non ergots are safer and work well as L-dopa adjuncts in patients with motor fluctuations and as monotherapy in mild to severe Parkinson's disease.

- Monotherapy with dopamine agonists carries a lower risk of motor problems than L-dopa. Dopamine agonists are recommended in this demographic since motor fluctuations are more common in younger patients. Due to the increased risk of psychosis and orthostatic hypotension in older adults using dopamine agonists, (Jankovic, J. (2008).

Examples:

GENRIC NAME	Starting dose (mg/day)	Maintenance dose (mg)
Pramipexole	0.125	1.5-4.5
Bromocriptine	2.5-5	15-40
Pramipexole ER	0.375	1.5-4.5
Ropinirole	0.75	9-24

Newly Introduced Drugs

PRODUODOPA (foslevodopa / foscarbidopa):

North Chicago, Illinois on January 09, 2024, AbbVie announced the release of PRODUODOPA ®(foslevodopa/ foscarbidopa) in the European Union. This medication is used to treat advanced Parkinson's disease with severe motor fluctuations and excessive movement or involuntary movement. It is intended for cases where other combinations of Parkinson's medications have not been effective. (Rosebraugh, M., et al. Foslevodopa/foscarbidopa). On October 18, 2024, the FDA gave the green light for a new injectable remedy for grownwith progressed Parkinson's complaint named Vyalev (also appertained to as Produodopa).

This new choice is created to help individualities who are floundering to control their symptoms with conventional medicines or operations. Parkinson's complaint is a complaint that impacts the capability to move and becomes more severe as time goes on. It occurs when the brain produces inadequate dopamine, a substance that regulates functions similar as mobility, memory, and emotional state. People with Parkinson's complaint experience symptoms similar as shaking, sluggish movements, rigid muscles, and difficulties with keeping their balance due to a lack of dopamine.

These symptoms can change during the day, with times when symptoms are manageable (appertained to as “ on ” times) and times when symptoms return and hamper movement(appertained to as “ off ” times). For individualities with severe Parkinson's complaint, handling these symptoms becomes indeed more gruelling, and in certain cases, their movements can come changeable (appertained to as dyskinesia), which makes diurnal conditioning more delicate.

Evaluation and therapeutic outcomes

Inform patients and caregivers on the importance of keeping track of drug dosages, administration timings, and the length of "on" and "off" periods.

- Track symptoms, adverse effects, and everyday living activities while customizing treatment. It is best to stop taking any concurrent drugs that can exacerbate behavioural, cognitive, motor, or fall problems.

4. Bromocriptine Use in Diabetic Patients Mechanism of Action

Studying the metabolism of migratory birds gave rise to the concept of utilizing bromocriptine to treat type 2 diabetes. It was observed that their insulin sensitivity and body fat reserves changed seasonally. In vertebrates, the temporal interplay of circadian neuroendocrine oscillations regulates insulin activity and body fat reserves. When food is scarce during hibernation, migration, and overwintering, many vertebrate species acquire obesity and insulin resistance (IR). Basal lipolytic activity rises as the body moves toward an insulin-resistant state in order to prevent the peripheral tissues from using glucose, and fat oxidation takes over. During extended periods of winter food shortage, hepatic glucose synthesis and gluconeogenesis increase to provide glucose to the central nervous system. During periods of seasonal hunger, this adaptability aids in survival. Animals become slim toward the conclusion of the season and return to the insulin-sensitive/glucose-tolerant phase. Numerous experimental findings suggest that circadian neuroendocrine rhythms are essential for the emergence of these seasonal variations. In particular, the obese/IR phenotype is thought to be caused by temporal shifts in the interaction of two different circadian brain oscillations, which are partially controlled by dopaminergic and serotonergic neurotransmitter activity, with decreased dopaminergic and increased serotonergic activity. These alterations in monoaminergic activity and concentrations take place in the ventromedial hypothalamus (VMH) and the hypothalamic suprachiasmatic nuclei (SCN), which operate as the mammalian circadian pacemaker. Numerous studies have shown that in animals that experience seasonal changes in metabolism, serotonin and noradrenergic levels and activity rise during the insulin-resistant state and revert to normal upon entering the insulin-sensitive state. Dopamine levels, on the other hand, are low when an individual is insulin-resistant and rise to normal after reverting to an insulin-sensitive state. When insulin-resistant animals receive intracerebral bromocriptine, their increased VMH noradrenergic and serotonergic levels drop, improving insulin sensitivity and lowering plasma glucose and adipocyte lipolysis. When the amazing therapeutic success of levodopa monotherapy was questioned a few years ago, bromocriptine was launched as the first FDA-approved adjunct medication to levodopa treatment for patients with Parkinson's disease who also had motor complications (abnormal movements) (Jankovic, J. (2008).

Conclusion

Parkinson's disease (PD) is still a difficult neurological illness that significantly lowers a patient's quality of life due to its advancing motor and non-motor symptoms. The disease's complicated pathogenesis, which includes Lewy bodies and the degradation of dopaminergic neurons in the substantia nigra, highlights the intricate interactions between hereditary, environmental, and metabolic variables. Even while our knowledge of Parkinson's disease has advanced significantly, a permanent cure is still elusive, and the major goal of current treatments is to reduce symptoms rather than stop the illness's progression. A range of pharmacologic treatments are now part of treatment regimens for Parkinson's disease (PD), with dopamine agonists like bromocriptine and levodopa being essential for controlling motor symptoms. Long-term therapy, however, frequently brings with it new difficulties, like the emergence of dyskinesias and motor irregularities. Furthermore, a complete therapy strategy that goes beyond dopamine replacement is needed for non-motor symptoms, which might include everything from sleep disruptions to cognitive impairments and autonomic dysfunctions. The intricacy of managing Parkinson's disease highlights the value of individualized, multifaceted treatment regimens that target both motor and nonmotor symptoms. The use of bromocriptine in individuals with concomitant type 2 diabetes mellitus (T2DM) is a hopeful advancement in the treatment of Parkinson's disease. Bromocriptine is a dopamine agonist that provides special metabolic advantages in addition to reducing Parkinson's disease symptoms. It offers a useful dual-approach treatment because of its ability to increase insulin sensitivity, decrease plasma glucose, and maybe lessen cardiovascular risks. This application demonstrates the need for novel treatments that take into account the complex nature of Parkinson's disease, particularly in patients who also have metabolic abnormalities. Bromocriptine is a prime example of how treating comorbid illnesses together can improve patient outcomes in clinical practice, especially when handling complicated cases that call for consideration of both neurological and metabolic health. To maximize therapeutic advantages and minimize side effects, it is crucial to regularly check for side effects, such as metabolic interactions, mental symptoms, and orthostatic hypotension. This paper's conclusion highlights the necessity of treating Parkinson's disease (PD) with a customized strategy that balances comorbidities, quality of life, and symptom control. Future studies should keep looking for novel drugs and combination therapies that could help reduce both motor and non-motor symptoms. For the time being, using already approved medications like bromocriptine in creative ways shows how important it is to customize care to meet the individual needs of every patient, providing a more comprehensive approach to Parkinson's disease management.

References

- Parkinson, J. (1817). "An Essay on the Shaking Palsy." *The Journal of Neuropsychiatry and Clinical Neurosciences*, 20(3), 301-309.
- Schapira, A. H. V., & Olanow, C. W. (2004). "Scientific and Clinical Advances in the Treatment of Parkinson's Disease." *Movement Disorders*, 19(5), 515-522.
- Aarsland, D., Brønnick, K., & Ehrt, U. (2011). "Neuropsychiatric Symptoms in Parkinson's Disease." *Movement Disorders*, 26(5), 646-653.
- "Parkinson's Disease." *The Lancet*, 386(9996), 896-912.
- Olanow, C. W., & Schapira, A. H. V. (2013). "Therapeutic Targets in Parkinson's Disease." *Movement Disorders*, 28(8), 1049-1060.
- De Maeyer, J., & Meskal, I. (2020). "The Role of Bromocriptine in Parkinson's Disease: Current Perspectives." *Neurodegenerative Disease Management*, 10(4), 197-209.
- Jankovic, J. (2008). "Medical Therapy for Parkinson's Disease." *Movement Disorders*, 23(S3), S522-S530.
- Grewal E. Bromocriptine: The new frontier in type 2 diabetes. Available at http://www.ijcci.info/flash/oct10/Diabetes_summit/
- Defronzo RA. Banting Lecture: From the triumvirate to the ominous octet: A new paradigm for the treatment of type 2 diabetes mellitus. *Diabetes*. 2009;58:773–95. doi: 10.2337/db09-9028. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Via MA, Chandra H, Araki T, Potenza MV, Skamagas M. Bromocriptine approved as the first medication to target dopamine activity to improve glycemic control in patients with type 2 diabetes. *Diabetes Metab Syndr Obes* 2010;3:43
- Grewal E. Bromocriptine: The new frontier in type 2 diabetes. Available at http://www.ijcci.info/flash/oct10/Diabetes_summit/
- Dopamine%20%20The%20new%20frontier%20%20in%20type. swf. [Last accessed on 2011 May 1].
- Southern LL, Cincotta AH, Meier AH, Bidner TD, Watkins KL. Bromocriptine-induced reduction of body fat in pigs. *J Anim Sci* 1990;68:931-6.
- Erminioc P. Ergot compounds and brain function: Neuroendocrine and neuropsychiatric aspects. In: Goldstein ML, editor. *Advances in Biochemical Psychopharmacology*. New York: Raven; 1980. p. 41-62.
- Luo S, Meier AH, Cincotta AH. Bromocriptine reduces obesity, glucose intolerance and extracellular monoamine metabolite levels in the ventromedial hypothalamus of Syrian hamsters. *Neuroendocrinology* 1998;68:1-10.

- Luo S, Luo J, Cincotta AH. Suprachiasmatic nuclei monoamine metabolism of glucose tolerant versus intolerant hamsters. *Neuroreport* 1999;10:2073-7.
- Gibson WT, Ebersole BJ, Bhattacharyya S et al. Mutational analysis of the serotonin receptor 5HT_{2c} in severe early-onset human obesity. *Can J Physiol Pharmacol* 2004; 82: 426–429.
- Zhou L, Sutton GM, Rochford JJ et al. Serotonin 2C receptor agonists improve type 2 diabetes via melanocortin-4 receptor signaling pathways. *Cell Metab* 2007; 6: 398–405.
- Holt RI, Peveler RC. Obesity, serious mental illness and antipsychotic drugs. *Diabetes Obes Metab* 2009; 11: 665–679.
- Day C, Bailey CJ. Effect of the antiobesity agent sibutramine in obese diabetic ob/ob mice. *Int J Obes Relat Metab Disord* 1998; 22: 619–623.
- Prasai MJ, George JT, Scott EM. Molecular clocks, type 2 diabetes and cardiovascular disease. *Diab Vasc Dis Res* 2008; 5: 89–95.
- Lam DD, Heisler LK. Serotonin and energy balance: molecular mechanisms and implications for type 2 diabetes. *Expert Rev Mol Med* 2007; 9: 1–24.
- Iravani, M.M., Kashefi, K., Mander, P., Rose, S., Jenner, P., 2002. Involvement of inducible nitric oxide synthase in inflammation-induced dopaminergic neurodegeneration. *Neuroscience* 110 (1), 49–58.
- Jankovic, J., 2005. Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations. *Mov. Disord.* 20 (11), S11–S16.
- Jellinger, K.S., 1999. The role of iron in neurodegeneration: prospects for pharmacotherapy of Parkinson's disease. *Drugs Aging* 14, 115–140. Jenner, P.G., Brin, M.F., 1998. Levodopa neurotoxicity: experimental studies versus clinical relevance. *Neurology* 50 (6), S39–S43 (discussion S44–S48)
- Hickey M. G., Demaerschalk B. M., Caselli R. J. et al. (2007) “Idiopathic” rapid-eyemovement sleep behavior disorder is associated with future development of neurodegenerative diseases. *Neurologist* 13, 98–101.
- Hirayama M. (2006) Sweating dysfunctions in Parkinson's disease. *J. Neurol.* 253(Suppl 7), VII/42–VII/47.
- Holroyd S., Currie L. and Wooten G. F. (2001) Prospective study of hallucinations and delusions in Parkinson's disease. *J. Neurol. Neurosurg. Psychiatry* 70, 734–738.
- Hughes A. J., Daniel S. E., Kilford L. and Lees A. J. (1992) Accuracy of clinical diagnosis of idiopathic study of 100 cases. *J. Neurol. Neurosurg. Psychiatry* 55, 181–184.
- Inzelberg R., Kipervasser S. and Korczyn A. D. (1998) Auditory hallucinations in Parkinson's disease. *J. Neurol. Neurosurg. Psychiatry* 64, 533–535.

- Iodice V., Low D. A., Vichayanrat E. and Mathias C. J. (2011) Cardiovascular autonomic dysfunction in MSA and Parkinson's disease: similarities and differences. *J. Neurol. Sci.* 310, 133–138.
- Irwin D. J., White M. R., Toledo J. B. et al. (2012) Neuropathologic substrates of Parkinson disease dementia. *Ann. Neurol.* 72, 587– 598.
- Rosebraugh, M., et al. Foslevodopa/foscarbidopa subcutaneous infusion maintains equivalent levodopa exposure to levodopa-carbidopa intestinal gel delivered to the jejunum.
- [FDA Approves New Treatment for Advanced Parkinson's Disease](#)
- Jankovic J. (2008) Parkinson's disease: clinical features and diagnosis. *J. Neurol. Neurosurg. Psychiatry* 79, 368–376.
- Jankovic J. and Stacy M. (2007) Medical management of levodopa associated motor complications in patients with Parkinson's disease. *CNS Drugs* 21, 677–692.
- Jankovic J. and Tintner R. (2001) Dystonia and parkinsonism. *Parkinsonism Relat. Disord.* 8, 109–121.
- Jost W. H. (2003) Autonomic dysfunction in idiopathic Parkinson's disease. *J. Neurol* 250(Suppl 1), 28–30.
- Jost W. H. (2010) Gastrointestinal dysfunction in Parkinson's disease. *J. Neurol. Sci.* 289, 69–73.
- Jost W. H. and Augustis S. (2015) Severity of orthostatic hypotension in the course of Parkinson's disease: no correlation with the duration of the disease. *Parkinsonism Relat. Disord.* 21, 314–316.